The effect of RBM10 deficiency on EGFR-mutant NSCLC established in this study sheds light on the role of tumor genetic heterogeneity in the multifaceted evolution of therapeutic resistance. The gene discussed is RBM10; the disease is non-small cell lung carcinoma.